moxifloxacin has been researched along with rifamycins in 4 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (rifamycins) | Trials (rifamycins) | Recent Studies (post-2010) (rifamycins) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 2,351 | 203 | 626 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bonora, S; Calcagno, A; Di Perri, G; Lucchini, A; Mondo, A; Trentini, L | 1 |
| Hsueh, PR; Ko, WC; Liao, CH; Lu, JJ | 1 |
| Ang, TL; Song, M | 1 |
| Alameer, R; Almaghrabi, RS; Almohaizeie, A; Alrajhi, AA; Alshehri, N; Nizami, I; Omrani, AS | 1 |
1 review(s) available for moxifloxacin and rifamycins
| Article | Year |
|---|---|
Second and third line treatment options for Helicobacter pylori eradication.
Topics: Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Moxifloxacin; Ofloxacin; Rifabutin; Rifamycins; Rifaximin; Salvage Therapy; Virulence Factors | 2014 |
3 other study(ies) available for moxifloxacin and rifamycins
| Article | Year |
|---|---|
Moxifloxacin for the treatment of HIV-associated tuberculosis in patients with contraindications or intolerance to rifamycins.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Aza Compounds; Contraindications; Drug Resistance, Bacterial; Fluoroquinolones; HIV Infections; Humans; Male; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Rifamycins; Treatment Outcome; Tuberculosis | 2008 |
Characterizations of clinical isolates of clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan.
Topics: Anti-Infective Agents; Aza Compounds; Bacterial Proteins; Clostridioides difficile; Fluoroquinolones; Gemifloxacin; Glycosides; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Rifamycins; Rifaximin; Taiwan; Vancomycin | 2012 |
Successful Use of Rifamycin-Sparing Regimens for the Treatment of Active Tuberculosis in Lung Transplant Recipients.
Topics: Ethambutol; Humans; Isoniazid; Lung; Lung Transplantation; Moxifloxacin; Pyrazinamide; Rifamycins; Transplant Recipients; Treatment Outcome; Tuberculosis | 2021 |